

March 20, 2023

Company Anicom Holdings, Inc.
 Representative Director Nobuaki Komori
 (Securities Code: 8715 TSE PRIME)
 Inquiries to Hiroshi Sato
 Corporate Planning Department,
 General Manager

Monthly Management Parameters, February 2023

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2022 (From April 1, 2022 to March 31, 2023)

	April	May	June	July	August	September
Net premiums written (previous year)	4,053 JPYmn (3,721 JPYmn)	4,332 JPYmn (4,061 JPYmn)	4,119 JPYmn (3,837 JPYmn)	4,085 JPYmn (3,789 JPYmn)	4,219 JPYmn (3,938 JPYmn)	4,253 JPYmn (3,949 JPYmn)
No. of policies in force (previous year)						
Renewal rate (previous year)						
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	17,080 (14,116)	17,971 (16,286)	17,258 (15,495)	16,915 (14,026)	17,199 (15,911)	17,675 (15,785)
No. of PARM hospitals*1 (previous year)	443 (229)	451 (239)	463 (266)	481 (298)	500 (318)	532 (329)
No. of patent applications (cumulative)*2 (previous year)	32 (11)	33 (14)	34 (16)	35 (18)	35 (19)	36 (20)

	October	November	December	January	February	March
Net premiums written (previous year)	4,291 JPYmn (3,979 JPYmn)	4,173 JPYmn (3,882 JPYmn)	4,270 JPYmn (3,973 JPYmn)	4,400 JPYmn (4,106 JPYmn)	4,207 JPYmn (3,972 JPYmn)	JPYmn (4,123 JPYmn)
No. of policies in force (previous year)			1,094,863 (-)	1,102,199 (-)	1,107,095 (-)	(-)
Renewal rate (previous year)			88.0% (-)	88.0% (-)	88.3% (-)	% (-)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	18,519 (16,438)	16,701 (15,115)	16,953 (15,031)	17,769 (16,812)	18,230 (16,302)	(16,945)
No. of PARM hospitals* ¹ (previous year)	544 (341)	552 (359)	576 (388)	591 (402)	612 (418)	(430)
No. of patent applications (cumulative)* ² (previous year)	38 (21)	40 (22)	41 (23)	44 (24)	46 (25)	(27)

*1 This is a key figure regarding the progress of the regenerative medicine business.

The "Research and Development Partnership for Animal Regenerative Medicine (PARM)" is a non-profit mutual benefit corporation. Its purpose is to take advantage of industry-government-academia collaboration in order to standardize each process of cell therapy services for domestic animals (dogs and cats) and achieve the practical application of a system that makes it possible for veterinarians at all kinds of medical facilities to provide safe and effective cell therapy services.

*2 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented company that prevents injuries and illnesses before they occur.

Since April 2022, we disclose the figure including the three patents inherited from Celltrust Animal Therapeutics Co., Ltd. which took over the business in FY2021.

(Reference) "Monthly Management Parameters" will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December, and March.